Bringing the fundamentals into focus…
Back to Ascendis Pharma A/S
How Ascendis Pharma A/S stacks up
ASND · against 1,336 other Healthcare companies
Valuation
36/ 100
Below the middle of the pack.
Ranked #850 of 1,337 · scores higher than 36% of peers
Bars: peers in each 10-point band of the valuation score133 peers with a valuation score of 30–39, including ASND · Click a bar to see the companies
Why valuation scores 36?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield, which is weaker than most Healthcare peers.
- less operating profit (EBITDA) for the company's total value: weaker than 62% of peers. EBITDA yield: 1.8% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 62% of peers. Free cash flow yield: 2.3% vs peer median 0.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -1.7% vs peer median 1.5%
Metric by metric
Position: dot = ASND, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ASND | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 5.2% | 1.5% | 79% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 1.8% | 4.2% | 38% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | 2.3% | -1.0% | 62% | 20% | |
| Book yieldHigher is better · 1,306 reported | Not reported | 37.9% | — | — | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around ASND| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 837 | 2.7B USD | 37 | 44 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score